Alle Meldungen
Abonnieren Sie alle Meldungen von Heska Corporation
Keine Meldung von Heska Corporation mehr verpassen.

15.03.2001 – 13:02

Heska Corporation

Patent granted for Heska Corporation's equine influenza vaccine

    Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced the recent issuance of a patent covering its equine influenza vaccine, Flu Avert(TM) I.N. vaccine.          (Photo: )          The vaccine, introduced by Heska in the United States in November 1999, has proven to be safe and effective in protecting horses from the most common strains of equine influenza. Flu Avert I.N. vaccine is a "modified live" vaccine which incorporates a "cold adapted" virus that replicates only in the upper regions of the horse's respiratory system and generates a strong immune response. However, because it is also temperature sensitive, the virus does not replicate at the higher temperatures found in the lungs or lower respiratory tract of the animal. Heska's vaccine is also unique in that a single administration using a nasal applicator, rather than a needle, provides effective protection from equine influenza.          The cold-adapted virus strains were developed at the University of Pittsburgh by Drs. Patricia W. Dowling and Julius S. Youngner, who are listed as the inventors on the patent (US Patent Number 6,177,082 B1). Heska obtained an exclusive license on the technology from the University of Pittsburgh in 1995, developed vaccine manufacturing protocols, designed the clinical trials and obtained U.S. regulatory approval for the product in November of 1999.          Robert Grieve, Chairman and Chief Executive Officer of Heska, said, "We are pleased to announce the issuance of this patent, as it has broad potential application for similar products that may be developed in the future. Flu Avert I.N. vaccine sales are showing strong growth in the U.S. and the product appears to be gaining momentum in the marketplace, as more and more equine veterinarians, trainers and horse owners discover just how safe and effective this product is.          "Flu Avert I.N. vaccine is another in a series of innovative products from Heska's deep research and development pipeline that address the unmet needs of companion animals. We continue to seek strategic relationships with parties outside of the United States in order to maximise the value of this unique product, and bring this much-needed vaccine to the maximum number of equine veterinarians, trainers and horse owners," said Grieve.          Heska (Nasdaq: HSKA) applies biotechnology to the large and growing companion animal health market. Veterinarians in the United States and Europe count on Heska for state-of-the-art pharmaceuticals, vaccines and diagnostic products for the testing and treatment of thousands of cats and dogs each year, as well as for diagnostic and patient monitoring instrumentation and supplies. Heska also operates a USDA- and FDA-licensed facility, which manufactures vaccines and pharmaceutical products. For additional information on Heska and its products, visit the company's web site at          With the exception of historical matters, this press release contains express or implied forward-looking information about Heska's technology and potential future revenue from its products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Heska to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Heska's achievement of these results may be affected by many factors, including among others, the following: uncertainties regarding the regulatory approval of products in markets outside of the United States, uncertainties regarding the outcome of sales and marketing efforts in the United States or the ability to successfully commercialise products in markets outside of the United States, uncertainties regarding the scope, enforceability and validity of patents and proprietary rights, which are subject to complex legal standards that vary from country to country and are subject to interpretation by administrative agencies and courts, competition, changes in business strategy or development plans, inability to market, sell or distribute products at currently projected costs and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 1999, in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2000 and in the Form S-3 registration statement filed on February 14, 2001.      ots Original Text Service: Heska Corporation Internet:

Contact: Ron Hendrick, Executive Vice President & CFO, ext. 4105, or Robert Grieve, Chairman & CEO, ext. 4155, of Heska Corporation, +1 970 493 7272; or Matthew Orsagh, Investor Relations, ext. 357, or Stephen Gendel, Media Relations, ext. 212, of Noonan/Russo Communications, Inc., +1 212 696 4455, for Heska Corporation      Photo: NewsCom:      PRN Photo Desk, +1 888-776-6555 or +1 201-369-3467      Web site:

Original-Content von: Heska Corporation, übermittelt durch news aktuell

Weitere Meldungen: Heska Corporation
Weitere Meldungen: Heska Corporation